Cardiovascular disease (CVD) causes 1 death every 3 minutes in England

Implementing effective lipid management for patients is one of the national priorities for the NHS in England in the prevention and management of Cardiovascular Disease (CVD). As set out in the Long Term Plan, its ambition is to prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years by improving detection and treatment of CVD risk factors such as high cholesterol.

We invite you to join the first of three Lipid Management Briefings from the Accelerated Access Collaborative (AAC).

The first briefing will be held on Monday 24th May 2021 at 14.00 and will focus on improvements and innovation in lipid management, and will introduce how novel therapies implemented via a population health management approach can support the Long Term Plan ambitions and address CVD health inequalities.

This Lipid Management Briefing is for local health system leaders in Integrated Care Systems (ICSs), Sustainability and Transformation Partnerships (STPs), Primary Care Networks (PCNs), and Academic Health Science Networks (AHSNs) as well as primary care health care professionals such as GPs, practice-based pharmacists and nurses, and CVD/lipid experts who will be leading on activity to improve lipid management for patients as part of this national priority.

Speakers include:

  • Dr Shahed Ahmad – National Clinical Director for Cardiovascular Disease Prevention at NHS England Improvement
  • Dr Tracey Vell MBE – Medical Director of Health Innovation Manchester, and Executive Lead for Primary Care at GM Health and Social Care Partnership
  • Matt Whitty – Director of Innovation Research and Life Sciences at NHS England and Improvement and CEO of the Accelerated Access Collaborative

The first session in the briefing will address the current challenges with lipid management in England and the national need for change driven by primary care through population health management approaches. The session will then cover the role of the AAC and AHSNs in supporting the health system to optimise lipid management and increase uptake and adoption of lipid lowering therapies to improve patient outcomes.

In January 2020 NHS England announced a ground-breaking, in-principle agreement with Novartis for the introduction of Inclisiran into the NHS following approval. In the last part of this session we will look at work underway in Manchester – an implementation study on Inclisiran and its implementation using a population health management approach.

The event will conclude with a panel discussion and opportunity for questions.

Please join this Teams Live Event to find out what this means for improving lipid management in your area.

Questions about this event?


Disclaimer: This meeting is part of a collaborative working agreement for lipid management between Novartis and NHS England and Improvement. Both Novartis and NHS England and Improvement contribute resources in the form of skills, expertise, project management and administrative activity.

Funding for the collaborative working programme is provided by Novartis. NHS England and Improvement retained editorial control of the agenda and content for this meeting.